In a bid to expand its pipeline of Personalized Healthcare
) acquired an exclusive worldwide license for the calreticulin
(CALR) biomarker from CeMM Vienna, the Research Center for
Molecular Medicine of the Austrian Academy of Sciences.
Qiagen retains a strong pipeline of promising biomarkers under
development for Personalized Healthcare tests pertaining to
rheumatoid arthritis, lung cancer, colorectal cancer,
glioblastoma, lymphoma and other cancers. Post acquisition of the
license, Qiagen will develop a molecular diagnostic test for CALR
mutations that will help healthcare providers to make more
informed therapeutic decisions.
According to the CeMM and Medical University of Vienna
research teams, mutations of the CALR biomarker are found in
approximately 15% of cases of myeloproliferative neoplasms
(MPNs), a group of blood disorders.
The proposed CALR diagnostic test is expected to be highly
compatible with Qiagen's kits for a key mutation of the Janus
kinase 2 (JAK2) gene. Qiagen already holds a license for the JAK2
V617F mutation, which is present in about 75% of patients with
MPN. Thus, the JAK2 and CALR biomarkers coupled together, should
offer a comprehensive and enhanced approach for healthcare
professionals to treat patients suffering from myeloprofilerative
Qiagen's Personalized Healthcare assays fall under
, an important customer class, which contributed 50% to Qiagen's
sales in 2013. This leading provider of advanced sample &
assay technologies has planned to develop tests for
identification of CALR mutations based on its Rotor-Gene Q MDx
Qiagen has been gaining momentum in its leadership in
Personalized Healthcare - a major growth driver in 2013. The
company kicked off 2014 with the launch of the new
IDH1/2 RGQ kit in Europe in January, and entered into a new
collaboration with Mayo Clinic to develop diagnostics for
cholangiocarcinoma (CCA, also known as bile duct cancer) by
utilizing biomarkers for IDH1 and IDH2 gene mutations.
With nearly 3 million people worldwide suffering from
myeloproliferative neoplasms, the proposed test to be developed
by Qiagen should have considerable demand in the market. Also,
with the launch of the first set of biofluid nucleic acid kits
scheduled in 2014, the company's prospects appear strong.
It is worth noting in this regard that Qiagen had announced a
strategic partnership with Exosome Diagnostics on Jul 23, 2013 to
develop an all-inclusive range of biofluid nucleic acid kits.
Qiagen presently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader healthcare sector
that warrant a look are
Myriad Genetics Inc.
ANI Pharmaceuticals, Inc
). All these companies sport a Zacks Rank #1 (Strong Buy).
AMGEN INC (AMGN): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.